These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 8547630)
61. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Greiner J; Ringhoffer M; Taniguchi M; Schmitt A; Kirchner D; Krähn G; Heilmann V; Gschwend J; Bergmann L; Döhner H; Schmitt M Exp Hematol; 2002 Sep; 30(9):1029-35. PubMed ID: 12225794 [TBL] [Abstract][Full Text] [Related]
62. A hematopoietic organ-specific 49-kD nuclear antigen: predominance in immature normal and tumor granulocytes and detection in hematopoietic precursor cells. Lee BC; Shav-Tal Y; Peled A; Gothelf Y; Jiang W; Toledo J; Ploemacher RE; Haran-Ghera N; Zipori D Blood; 1996 Mar; 87(6):2283-91. PubMed ID: 8630389 [TBL] [Abstract][Full Text] [Related]
63. Abnormal expression of N-CAM (CD56) adhesion molecule on myeloid and progenitor cells from chronic myeloid leukemia. Lanza F; Bi S; Castoldi G; Goldman JM Leukemia; 1993 Oct; 7(10):1570-5. PubMed ID: 7692192 [TBL] [Abstract][Full Text] [Related]
64. Expression of Thy-1 on human hematopoietic progenitor cells. Craig W; Kay R; Cutler RL; Lansdorp PM J Exp Med; 1993 May; 177(5):1331-42. PubMed ID: 7683034 [TBL] [Abstract][Full Text] [Related]
65. The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0): reduced immunogenicity and high frequency of CD34+/CD38- leukemic progenitors. Costello R; Mallet F; Chambost H; Sainty D; Arnoulet C; Gastaut JA; Olive D Leukemia; 1999 Oct; 13(10):1513-8. PubMed ID: 10516751 [TBL] [Abstract][Full Text] [Related]
66. Isotype controls in the analysis of lymphocytes and CD34+ stem and progenitor cells by flow cytometry--time to let go! Keeney M; Gratama JW; Chin-Yee IH; Sutherland DR Cytometry; 1998 Dec; 34(6):280-3. PubMed ID: 9879645 [No Abstract] [Full Text] [Related]
67. Immunologic purging of autologous peripheral blood stem cell products based on CD34 and CD133 expression can be effectively and safely applied in half of the acute myeloid leukemia patients. Feller N; van der Pol MA; Waaijman T; Weijers GW; Westra G; Ossenkoppele GJ; Schuurhuis GJ Clin Cancer Res; 2005 Jul; 11(13):4793-801. PubMed ID: 16000576 [TBL] [Abstract][Full Text] [Related]
68. Leukemic burden in subpopulations of CD34+ cells isolated from the mobilized peripheral blood of alpha-interferon-resistant or -intolerant patients with chronic myeloid leukemia. Van den Berg D; Wessman M; Murray L; Tong J; Chen B; Chen S; Simonetti D; King J; Yamasaki G; DiGiusto R; Gearing D; Reading C Blood; 1996 May; 87(10):4348-57. PubMed ID: 8639795 [TBL] [Abstract][Full Text] [Related]
69. CD34+ cells and CD34+CD38- subset from mobilized blood show different patterns of adhesion molecules compared to those from steady-state blood, bone marrow, and cord blood. Sovalat H; Racadot E; Ojeda M; Lewandowski H; Chabouté V; Hénon P J Hematother Stem Cell Res; 2003 Oct; 12(5):473-89. PubMed ID: 14594504 [TBL] [Abstract][Full Text] [Related]
70. Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias. Virgo P; Denning-Kendall PA; Erickson-Miller CL; Singha S; Evely R; Hows JM; Freeman SD Br J Haematol; 2003 Nov; 123(3):420-30. PubMed ID: 14617000 [TBL] [Abstract][Full Text] [Related]
71. CDCP1 identifies a broad spectrum of normal and malignant stem/progenitor cell subsets of hematopoietic and nonhematopoietic origin. Bühring HJ; Kuçi S; Conze T; Rathke G; Bartolović K; Grünebach F; Scherl-Mostageer M; Brümmendorf TH; Schweifer N; Lammers R Stem Cells; 2004; 22(3):334-43. PubMed ID: 15153610 [TBL] [Abstract][Full Text] [Related]
72. Antigens differentially expressed on surface and cytoplasmic structures of human myeloid cells. Fitz-Gibbon L; Shematek G; Sullivan AK Leuk Res; 1985; 9(1):123-34. PubMed ID: 3857403 [TBL] [Abstract][Full Text] [Related]
73. [Detection of strain-specific antigens on normal myeloid stem cells and on leukemic blasts using cytotoxic monoclonal antibodies and complement]. Nolasco I; Hibbin JA; Polli N; Goldman JM Sangre (Barc); 1985; 30(2):159-67. PubMed ID: 4012517 [No Abstract] [Full Text] [Related]
74. Characterisation and biology of normal human haematopoietic stem cells. Ploemacher RE Haematologica; 1999 Jun; 84 Suppl EHA-4():4-7. PubMed ID: 10907454 [No Abstract] [Full Text] [Related]
75. Differences in phycoerythrin- or fluorescein-isothiocyanate conjugated 8G12 on CD34+ cell evaluation. Ortuño F; Ferrer F; Lozano ML; Heras I; Moraleda JM; Vicente V Haematologica; 1997; 82(3):334-5. PubMed ID: 9234583 [TBL] [Abstract][Full Text] [Related]
76. Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117). Blair A; Sutherland HJ Exp Hematol; 2000 Jun; 28(6):660-71. PubMed ID: 10880752 [TBL] [Abstract][Full Text] [Related]
77. Immunotyping of blasts in refractory anaemia with excess of blasts. Oertel J; Kleiner S; Huhn D Br J Haematol; 1993 Jun; 84(2):305-9. PubMed ID: 7691147 [TBL] [Abstract][Full Text] [Related]
78. Myeloid antigens and antigen densities in mice and men. Jäger G; Hoffmann-Fezer G; Rodt H; Huhn D; Thiel E; Thierfelder S Haematol Blood Transfus; 1977; 20():109-16. PubMed ID: 273001 [No Abstract] [Full Text] [Related]
79. Preparation of immunoliposomes directed against CD34 antigen as target. Mercadal M; Carrion C; Domingo JC; Petriz J; Garcia J; de Madariaga MA Biochim Biophys Acta; 1998 Apr; 1371(1):17-23. PubMed ID: 9565652 [TBL] [Abstract][Full Text] [Related]
80. Cloning of bovine CD34 cDNA. Zhou JH; Hikono H; Ohta M; Sakurai M J Vet Med Sci; 2001 Sep; 63(9):1051-3. PubMed ID: 11642278 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]